To the Editor,
We recently read with great interest the article by Yilmaz and Uzun,1 describing the efficacy and safety of low dose thrombolytic therapy (TT) in patients with acute submassive pulmonary embolism (PE). We would like to emphasize a few points in light of current evidence.
PE is one of the most frequently reported thrombotic complications,2 and is more prevalent in critically ill patients with coronavirus disease 2019 (COVID-19). Thirty-day results have shown that patients with COVID-19 and PE received no significant benefit from empirically administered prophylactic anticoagulants at moderate doses against venous thrombosis or mortality.3 In submassive …
Log in using your username and password
Log in through your institution
PURCHASE SHORT TERM ACCESS
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.